B. Riley lowered the firm’s price target on Arrowhead (ARWR) to $38 from $51 and keeps a Buy rating on the shares following the fiscal Q1 report. The firm says Ionis Pharmaceuticals’ (IONS) Tryngolza early launch trends to offer visibility into Arrowhead’s near-term commercial prospects.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead Pharmaceuticals: Promising Pipeline Amidst Cautious Financial Outlook Warrants Hold Rating
- Arrowhead Pharmaceuticals: Promising Drug Approval and Expanding Pipeline Justify Buy Rating
- Arrowhead Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
- Arrowhead Pharmaceuticals: Promising Pipeline and Strategic Developments Drive Buy Rating
- Arrowhead Pharmaceuticals Reports Q1 2025 Financial Results